



NDA 8697/S-032 and S-033
NDA 9866/S-098 and S-105

SUPPLEMENT APPROVAL

Pfizer, Inc.
235 East 42nd Street
New York, NY 10017

Attention: Shai Srulovich, Pharm.D.
Senior Manager
Worldwide Safety and Regulatory

Dear Dr. Srulovich:

Please refer to your Supplemental New Drug Applications (sNDAs) dated and received October 16, 2013 (NDA 8697/S-032), August 28, 2014 (NDA 8697/S-033), September 9, 2013 (NDA 9866/S/098), and August 28, 2014 (NDA9866/S-105) and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Cortef (hydrocortisone) and SoluCortef (hydrocortisone sodium succinate)

These Prior Approval supplemental new drug applications provide for the following revisions to the USPI:

NDA 8697/S-032 and NDA 9866/S-098 - Addition of Central Serous Chorioretinopathy to the Warning Section and addition of Epidural Lipomatosis and Pheochromocytoma to the Precautions section.

NDA 8697/S-033 and NDA 9866/S-105 - Addition of Epidural Lipomatosis, Central Serous Chorioretinopathy and leukocytosis to the Adverse Reactions Section, removal of text regarding impaired mineralocorticoid secretion from the Precautions Section and addition of non-clinical information regarding impairment of fertility. Pfizer also proposed additional minor changes throughout the labeling.

APPROVAL & LABELING

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your applications, you are exempt from this requirement.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Captain Christine Ford, Regulatory Project Manager, at (301) 796-3420.

Sincerely,

{See appended electronic signature page}

Sally Seymour, M.D.
Deputy Director for Safety
Division of Pulmonary, Allergy, and Rheumatology
Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SALLY M SEYMOUR
09/08/2016